INDIGO Analysis Demonstrates Consistent Vorasidenib Benefit Across IDH Variant Allele Frequency Subgroups
Clinical Summary:
-
Design/Population: This biomarker analysis of the randomized, double-blind phase 3 INDIGO trial evaluated the relationship between baseline IDH1/2 variant allele frequency (VAF), tumor co-mutations, and progression-free survival (PFS) among patients with residual or recurrent grade 2 IDH-mutant astrocytoma or oligodendroglioma receiving vorasidenib or placebo.
-
Key Outcomes: Vorasidenib improved PFS compared with placebo in both lower and higher baseline IDH1/2 VAF subgroups. Baseline co-mutation burden was low and similar between treatment arms, while CDKN2A homozygous deletions were detected in only 2 patients.
-
Clinical Relevance: These findings suggest that the PFS benefit of vorasidenib extends across baseline IDH1/2 VAF subgroups, supporting its activity in grade 2 IDH-mutant glioma without evidence from this analysis that lower or higher baseline VAF should independently determine treatment selection.
Results from a biomarker analysis of the phase 3 INDIGO trial demonstrated that vorasidenib improved progression-free survival (PFS) compared with placebo in patients with grade 2 IDH-mutant glioma regardless of baseline IDH1/2 variant allele frequency (VAF), supporting consistent treatment benefit across molecularly defined subgroups.
These results were presented by Timothy Cloughesy, MD, University of California, Los Angeles, California, at the Society for Neuro-Oncology (SNO) Annual Meeting.
The analysis builds on previously reported INDIGO findings demonstrating a significant improvement in radiographic PFS with vorasidenib compared with placebo (hazard ratio [HR], 0.39; 95% confidence interval [CI], 0.27 to 0.56; one-sided P = .000000067). The trial also met its key secondary end point of time to next intervention.
In this double-blind trial, 331 patients aged 12 years or older with residual or recurrent grade 2 IDH1 (n = 315) or IDH2 (n = 16) mutated astrocytoma (n = 159) or oligodendroglioma (n = 172) were randomized 1:1 to receive either 40 mg of once daily vorasidenib (n = 168) or placebo (n = 163) in 28-day cycles. Eligible patients had measurable non-enhancing disease and had not received prior treatment for glioma.
IDH mutation status was centrally confirmed using an investigational clinical trial assay detecting IDH1 R132H/C/G/S/L or IDH2 R172K/M/W/S/G variants. Pretreatment archival tumor tissue underwent next-generation sequencing to assess CDKN2A/B homozygous deletions and additional tumor co-mutations.
For the biomarker analysis, patients were divided into lower and higher baseline IDH1/2 VAF subgroups using the median VAF of 0.377 as the cutoff.
Vorasidenib improved median PFS compared with placebo in both VAF subgroups, with a statistically significant benefit observed among patients with lower baseline VAF (one-sided P = .0116) and higher baseline VAF (one-sided P < .0001).
These findings suggest that the PFS benefit observed with vorasidenib was maintained across lower and higher baseline IDH1/2 VAF subgroups.
Baseline co-mutation profiles were similar between treatment arms, with a median of 4 co-mutations in known or likely oncogenic genes across both groups.
CDKN2A homozygous deletion was identified in only 2 patients, both of whom were assigned to placebo. The low prevalence of CDKN2A homozygous deletions limited the ability to assess their potential association with treatment outcomes.
The investigators concluded that vorasidenib prolonged PFS compared with placebo in patients with grade 2 IDH1/2-mutant glioma irrespective of baseline IDH1/2 VAF, reinforcing the efficacy of mutant IDH inhibition across the evaluated molecular subgroups.
Source:
Cloughesy T, Mellinghoff I, van den Bent M, et al. A randomized double-blind phase 3 study of vorasidenib vs placebo in patients with mutant IDH1/2 diffuse glioma (INDIGO): Exploratory analysis of variant allele frequency and progression-free survival. Presented at the SNO Annual Meeting. November 12-15, 2026; Philadelphia, Pennsylvania. Abstract CTNI-51.


